Literature DB >> 31498775

Rapidly maturing fentanyl clearance in preterm neonates.

Swantje Völler1, Robert B Flint2,3,4, Peter Andriessen5, Karel Allegaert6, Luc J I Zimmermann7, Kian D Liem8, Birgit C P Koch4, Sinno H P Simons2, Catherijne A J Knibbe1,9.   

Abstract

BACKGROUND: Fentanyl is frequently used off-label in preterm newborns. Due to very limited pharmacokinetic and pharmacodynamic data, fentanyl dosing is mostly based on bodyweight. This study describes the maturation of the pharmacokinetics in preterm neonates born before 32 weeks of gestation.
METHODS: 442 plasma samples from 98 preterm neonates (median gestational age: 26.9 (range 23.9-31.9) weeks, postnatal age: 3 (range 0-68) days, bodyweight 1.00 (range 0.39-2.37) kg) were collected in an opportunistic trial and fentanyl plasma levels were determined. NONMEM V.7.3 was used to develop a population pharmacokinetic model and to perform simulations.
RESULTS: Fentanyl pharmacokinetics was best described by a two-compartment model. A pronounced non-linear influence of postnatal and gestational age on clearance was identified. Clearance (L/hour/kg) increased threefold, 1.3-fold and 1.01-fold in the first, second and third weeks of life, respectively. In addition, clearance (L/hour/kg) was 1.4-fold and 1.7-fold higher in case of a gestational age of 28 and 31 weeks, respectively, compared with 25 weeks. Volume of distribution changed linearly with bodyweight and was 8.7 L/kg. To achieve similar exposure across the entire population, a continuous infusion (µg/kg/hour) dose should be reduced by 50% and 25% in preterm neonates with a postnatal age of 0-4 days and 5-9 days in comparison to 10 days and older.
CONCLUSION: Because of low clearance, bodyweight-based dosages may result in fentanyl accumulation in neonates with the lowest postnatal and gestational ages which may require dose reduction. Together with additional information on the pharmacodynamics, the results of this study can be used to guide dosing. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  neonatology; pharmacology

Mesh:

Substances:

Year:  2019        PMID: 31498775     DOI: 10.1136/archdischild-2018-315920

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  10 in total

1.  Interventions for the management of Pain and Sedation in Newborns undergoing Therapeutic hypothermia for hypoxic-ischemic encephalopathy (IPSNUT): protocol of a systematic review.

Authors:  Pyrola Bäcke; Matteo Bruschettini; Ylva Thernström Blomqvist; Emma Olsson
Journal:  Syst Rev       Date:  2022-05-23

Review 2.  Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Authors:  Siavosh Naji-Talakar; Sheena Sharma; Leslie A Martin; Derek Barnhart; Bhagwat Prasad
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

3.  Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population.

Authors:  Michael L Williams; Prince J Kannankeril; Joseph H Breeyear; Todd L Edwards; Sara L Van Driest; Leena Choi
Journal:  Clin Pharmacol Ther       Date:  2022-01-03       Impact factor: 6.903

4.  Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus.

Authors:  Aline G J Engbers; Robert B Flint; Swantje Völler; Johan C A de Klerk; Irwin K M Reiss; Peter Andriessen; Kian D Liem; Pieter L J Degraeuwe; Siska Croubels; Joske Millecam; Karel Allegaert; Sinno H P Simons; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.335

Review 5.  Practical approaches to sedation and analgesia in the newborn.

Authors:  Christopher McPherson; Cynthia M Ortinau; Zachary Vesoulis
Journal:  J Perinatol       Date:  2020-11-29       Impact factor: 2.521

6.  Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial).

Authors:  Serife Kurul; H Rob Taal; Robert B Flint; Jan Mazela; Irwin K M Reiss; Karel Allegaert; Sinno H P Simons
Journal:  BMC Pediatr       Date:  2021-11-18       Impact factor: 2.125

7.  Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study.

Authors:  Yunjiao Wu; Swantje Völler; Robert B Flint; Sinno H P Simons; Karel Allegaert; Vineta Fellman; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2021-11-13       Impact factor: 5.577

Review 8.  Assessment and Management of Pain in Preterm Infants: A Practice Update.

Authors:  Marsha Campbell-Yeo; Mats Eriksson; Britney Benoit
Journal:  Children (Basel)       Date:  2022-02-11

9.  Fentanyl Exposure in Preterm Infants: Five-Year Neurodevelopmental and Socioemotional Assessment.

Authors:  Kimberly P Mills; Rachel E Lean; Christopher D Smyser; Terrie Inder; Cynthia Rogers; Christopher C McPherson
Journal:  Front Pain Res (Lausanne)       Date:  2022-03-01

Review 10.  The influence of pain, agitation, and their management on the immature brain.

Authors:  Christopher McPherson; Steven P Miller; Mohamed El-Dib; An N Massaro; Terrie E Inder
Journal:  Pediatr Res       Date:  2020-01-02       Impact factor: 3.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.